Welcome to our dedicated page for EyePoint news (Ticker: EYPT), a resource for investors and traders seeking the latest updates and insights on EyePoint stock.
EyePoint, Inc. develops and commercializes therapeutics for serious retinal diseases as a clinical-stage biopharmaceutical company. Its lead product candidate, DURAVYU (vorolanib intravitreal insert), is an investigational sustained-delivery treatment that uses bioerodible Durasert E technology and is being studied for wet age-related macular degeneration and diabetic macular edema.
Recurring EyePoint news covers clinical program updates, financial results, FDA naming and product-status disclosures, manufacturing and commercial-readiness topics, investor presentations, and equity inducement grants under Nasdaq Listing Rule 5635(c)(4). Company updates also address cash resources, corporate development activity, and disclosures tied to its Nasdaq-listed common stock.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced the selection of a late-breaking abstract for the Phase 1 DAVIO trial of EYP-1901 in wet age-related macular degeneration (AMD) for presentation at the American Academy of Ophthalmology 2021 Annual Meeting, scheduled for November 12-15, 2021.
The presentation will feature topline data and is set for November 13, 2021, at 9:07 AM CST, presented by David S. Boyer MD. EYP-1901 aims to provide sustained delivery treatment via a single injection, with key endpoints including safety and visual acuity.
EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT) announced its senior management will present at four upcoming conferences. The presentations include:
- Ophthalmology Futures Euro Forums 2021 on September 8, 2021, featuring Jay Duker, M.D.
- H.C. Wainwright 23rd Annual Global Investor Conference on September 13, 2021.
- Cantor Fitzgerald Virtual Global Healthcare Conference on September 29, 2021.
- Benzinga Healthcare Small Cap Conference on September 30, 2021.
Recordings and webcasts will be available on their website.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that CEO Nancy Lurker will present at the H.C. Wainwright Ophthalmology Virtual Conference on August 17, 2021. The presentation will be accessible for on-demand viewing starting at 9:00 a.m. ET on the company’s website, with a replay available for 90 days. EyePoint focuses on innovative therapeutics for serious eye disorders, leveraging its Durasert® technology. The company’s current portfolio includes YUTIQ® and DEXYCU®, targeting chronic non-infectious uveitis and postoperative inflammation, respectively.
EyePoint Pharmaceuticals (EYPT) reported a substantial 136% increase in net product revenues to $8.7 million for Q2 2021 compared to $3.7 million in Q2 2020. The company's Phase 1 DAVIO trial for EYP-1901, a treatment for wet AMD, has shown positive 30-day safety data, with no serious adverse events reported. Customer demand for DEXYCU and YUTIQ surged, with DEXYCU achieving a record of 10,900 units sold, a 404% increase year-over-year. However, operating expenses rose to $20 million, contributing to a net loss of $10 million for the quarter.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has formed an Executive Scientific Advisory Board (SAB) chaired by Dr. Carl Regillo, a distinguished retinal surgeon. The SAB includes acclaimed members from prestigious institutions like Mayo Clinic and Duke University. This board aims to guide EyePoint's management in advancing its ocular product pipeline, notably the Phase 1 DAVIO trial for EYP-1901, a potential treatment for wet age-related macular degeneration. The board's collective expertise is expected to enhance the company's scientific strategy and improve patient outcomes.
EyePoint Pharmaceuticals (NASDAQ: EYPT) will host a conference call on August 4, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and recent business highlights. Investors can join the call by dialing (877)-312-7507 for domestic calls or (631)-813-4828 for international calls, using conference ID 1861354. The event will also be available via a live audio webcast on the company’s website. EyePoint is focused on innovative therapeutics for serious eye disorders and utilizes its proprietary Durasert® technology for extended drug delivery.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced a nine-month extension of DEXYCU®'s pass-through payment status following a draft ruling by the Centers for Medicare and Medicaid Services (CMS). This extension, set to last until December 31, 2022, aids in the coverage of outpatient drugs during cataract surgeries, impacting approximately 60% of Medicare Part B patients. The final ruling from CMS is expected in November 2021. CEO Nancy Lurker expressed optimism about the extension, emphasizing its significance for DEXYCU's commercial strategy.
EyePoint Pharmaceuticals (NASDAQ: EYPT) has reported positive safety results from its Phase 1 clinical trial of EYP-1901, aimed at treating wet age-related macular degeneration (wet AMD). The trial involved 17 patients and showed no serious adverse events after 30-day follow-ups. The company anticipates releasing interim efficacy results in Q4 2021 and plans to initiate trials for diabetic retinopathy and retinal vein occlusion. EYP-1901 utilizes proprietary Durasert® technology for sustained drug delivery, demonstrating the company's commitment to advancing eye disorder treatments.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced that the American Medical Association accepted a new Category III CPT code (0X78T) for drug administration in the eye, effective January 1, 2022. This code provides a reimbursement pathway for DEXYCU, the first FDA-approved sustained-release intracameral steroid for postoperative inflammation treatment. The approval is seen as a significant step toward increased adoption of DEXYCU, enhancing its market presence and financial prospects.
EyePoint Pharmaceuticals (NASDAQ: EYPT) announced its inclusion in the small-cap Russell 2000® Index and the broader Russell 3000® Index, effective June 28, 2021. This addition reflects the company’s position among approximately 2,000 smaller companies based on market capitalization.
The Russell indexes are critical benchmarks for investment strategies, managing $10.6 trillion in assets. EyePoint focuses on therapeutics for serious eye disorders, leveraging its proprietary Durasert® technology and two commercial products, YUTIQ® and DEXYCU®.